Scoop: To fund Covid-19 nasal vac­cine boost­er, Yale spin­out snags Se­ries A

A biotech work­ing to cre­ate an in­tranasal vac­cine boost­er for the on­go­ing Covid-19 pan­dem­ic has raised a Se­ries A, the start­up’s CEO con­firmed to End­points News.

Known as Xanadu Bio, the com­pa­ny was spun out of Yale Uni­ver­si­ty. The raise will bankroll non-hu­man pri­mate stud­ies for an in­tranasal spike mR­NA vac­cine boost­er, CEO and founder Bruce Turn­er told End­points via email.

A Dec. 27 SEC fil­ing out­lines a $30 mil­lion round for the Glad­wyne, Penn­syl­va­nia biotech. Turn­er de­clined to dis­cuss the fund­ing or the names of the com­pa­ny’s in­vestors, but said the com­pa­ny has “run­way un­til late 2024.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.